entertainment -WSS

entertainment

author：fashion 2025-08-28 13:05:45 - browse：5449

A Exterior of the new Ultragenyx biomanufacturing plant. -- biotech coverage from STAT — Jonathan Wiggs /Globe Staff

Ultragenyx said Thursday afternoon that its gene therapy for a rare liver ailment, glycogen disease type 1A, succeeded in a Phase 3 trial, setting up a potential approval.

Patients with GSD1a, as the condition is often known, have a genetic mutation that prevents them from adequately maintaining blood sugar levels. Once considered fatal, GSD1a can now be controlled with regular doses of cornstarch. But if patients miss a dose, there can be significant, even life-threatening, complications.

In the 49-person, randomized study, patients who received the Ultragenyx drug were able to take 41% less cornstarch after 48 weeks than they did at the start. Patients on placebo took only 10% less. The difference was statistically significant. Five patients were not included in the analysis, as three dropped out and the company didn’t have 48-week data from two.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： ProMED sees offers of support, but its future remains unclear

leisure time

WSS

An interview with Robert F. Kennedy Jr. on vaccines

FDA scientists endorse Pfizer/BioNTech Covid

Flint parents haunted by uncertainty, fears of lead poisoning

FDA scientists endorse Pfizer/BioNTech Covid

Florida officials tell state schools to teach AP Psychology 'in its entirety'

ActiGraph execs on goal of drug approvals with digital endpoints

entertainment

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

George Santos makes 1st court appearance after pleading not guilty to 13 counts

How I helped Pfizer think through the ethics of Viagra

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Living with Hashimoto's and celiac disease, and med school, too

FDA approval of Sarepta Duchenne genetic therapy gives me hope

2 officers injured in shooting in Orlando, police say

Novavax promises a turnaround & Lilly roils the obesity market

Biotech startup Celsius cuts 75% of staff ahead of first trial start

23andMe had bad news about my health. I wish a person had delivered it

FDA approves first treatment for ultra

explore

'Null' research findings aren't empty of meaning. Let's publish them

ActiGraph execs on goal of drug approvals with digital endpoints

As Maui death toll rises, number of missing remains unclear

Medicare slashes safety net hospital payments by nearly $1 billion

Medicare slashes safety net hospital payments by nearly $1 billion

A controversial new treatment promises to make little people taller

knowledge

focus

leisure time

leisure time